HTB | HIV i-Base

HTB

HTB: no. 4 – plus HIV and COVID-19 (1 April 2021)

Featured HTB: no. 4 – plus HIV and COVID-19 (1 April 2021) 1 April 2021. Related: Editorial, Early access.
Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP 1 April 2021. Related: Conference reports, Antiretrovirals, CROI 2021 (virtual).
Featured HTB: no. 3 – plus HIV and COVID-19 (12 March 2021) 12 March 2021. Related: Editorial, Special reports.
Featured HTB: no. 2 – plus HIV and COVID-19 (24 February 2021) 24 February 2021. Related: Editorial.
Featured HTB: no. 1 – plus HIV and COVID-19 (22 January 2021) 22 January 2021. Related: Editorial.
Featured HTB: no. 13/14 – HIV and COVID-19: issue 10 (9 December 2020) 9 December 2020. Related: Editorial.
Featured HTB: no. 12 – HIV and COVID-19: issue 9 (11 November 2020) 11 November 2020. Related: Editorial.
Featured In Memory: Timothy Ray Brown, the Berlin patient, the first person to be cured of HIV 14 October 2020. Related: In Memory.
US post-authorisation safety data on Pfizer and Moderna vaccines 15 April 2021. Related: Early access, COVID-19: vaccine research, COVID-19.
US CDC includes HIV as medical criteria for priority to COVID-19 vaccines 15 April 2021. Related: Early access, COVID-19: guidelines, COVID-19.
NICE guidelines on management of chronic pain: exercise but not opiods 9 April 2021. Related: Early access, Guidelines, Side effects, OIs, coinfections and complications.
Bar opening in the US: 100 guests linked to at least 46 cases of COVID-19 9 April 2021. Related: Early access, COVID-19: transmission & prevention, COVID-19.
i-Base appeal: please support i-Base with £5 or £10 a month 1 April 2021. Related: Editorial.
28th Conference on Retroviruses on Opportunistic Infections (CROI 2021) 1 April 2021. Related: Conference reports.
CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF 1 April 2021. Related: Conference reports, Pregnancy, CROI 2021 (virtual).
CROI 2021: New compounds for prevention and treatment of COVID-19 1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study 1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study 1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study 1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study 1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
CROI 2021: Presentations from the LEAP workshop 2021 1 April 2021. Related: Conference reports, Other news, CROI 2021 (virtual).
CROI 2021: Presentations on NATAP.org 1 April 2021. Related: Conference reports, Other news, CROI 2021 (virtual).
Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir 1 April 2021. Related: Antiretrovirals.
Calls to reverse proposed UK cuts to global health research 1 April 2021. Related: Other news.
BHIVA guidelines on COVID-19 vaccines and people living with HIV: DRAFT online for comment 1 April 2021. Related: Guidelines, COVID-19: guidelines, COVID-19.
BHIVA advice on access to COVID-19 vaccines and shielding in the UK 1 April 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
US phase 3 results enable FDA review of the Oxford/AstraZeneca vaccine 1 April 2021. Related: COVID-19: vaccine research, COVID-19.
Future meetings and webinars 2021 1 April 2021. Related: Future meetings.
HTB: no.4 – plus HIV and COVID-19 (1 April 2021) 1 April 2021. Related: PDFs.
In Memory: Dr Charles Boucher, leading HIV doctor, researcher and educator 12 March 2021. Related: In Memory.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) 12 March 2021. Related: Conference reports, Conference index, CROI 2021 (virtual).
CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV 12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19, CROI 2021 (virtual).
CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access… 12 March 2021. Related: Conference reports, Other news, CROI 2021 (virtual).
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance 12 March 2021. Related: Conference reports, Antiretrovirals, CROI 2021 (virtual).
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021 12 March 2021. Related: Conference reports, Antiretrovirals, CROI 2021 (virtual).
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission 12 March 2021. Related: Conference reports, HIV prevention and transmission, CROI 2021 (virtual).
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial 12 March 2021. Related: Conference reports, Treatment strategies, CROI 2021 (virtual).
CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated… 12 March 2021. Related: Conference reports, Virology, CROI 2021 (virtual).
CROI 2021: Community HIV cure workshops online 12 March 2021. Related: Conference reports, Cure research, CROI 2021 (virtual).
Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART 12 March 2021. Related: Side effects, OIs, coinfections and complications.
Janssen/J&J vaccine against COVID-19 is approved in the EU 12 March 2021. Related: COVID-19: vaccine research, COVID-19.
Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study 12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia 12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study 12 March 2021. Related: COVID-19: investigational drugs, COVID-19.
HTB: no.3 – plus HIV and COVID-19 (12 March 2021) 12 March 2021. Related: PDFs.
In memory: Elias Phiri, community HIV and TB advocate 24 February 2021. Related: In Memory.
In memory: Dr Joseph Sonnabend, pioneer HIV activist and researcher 24 February 2021. Related: In Memory.
Timothy Ray Brown: a virtual memorial 24 February 2021. Related: In Memory.
R4P virtual conference (2021) 24 February 2021. Related: Conference reports, HIV prevention and transmission, Conference index, R4P 2021 Virtual.
VRC01 antibody only prevents minority of HIV infections: AMP study results 24 February 2021. Related: Conference reports, HIV prevention and transmission, R4P 2021 Virtual.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS) 24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission, R4P 2021 Virtual.
Promising data for multipurpose technologies to prevent HIV and pregnancy 24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission, R4P 2021 Virtual.
12th International Workshop on HIV paediatrics 24 February 2021. Related: Conference reports, Conference index, 12th Paediatric HIV 2020.
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1 24 February 2021. Related: Conference reports, Paediatric care.